A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.